{
    "clinical_study": {
        "@rank": "8389", 
        "arm_group": {
            "arm_group_label": "Velcalcetide", 
            "arm_group_type": "Experimental", 
            "description": "Investigational drug product is supplied as a sterile, preservative-free, aqueous solution for injection."
        }, 
        "brief_summary": {
            "textblock": "This is a multicenter, single-arm, extension study to characterize the long-term safety and\n      tolerability of velcalcetide in the treatment of SHPT in subjects with CKD on hemodialysis."
        }, 
        "brief_title": "To Assess the Long-term Safety of Velcalcetide in the Treatment of SHPT in Subjects With CKD on Hemodialysis", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperparathyroidism, Secondary", 
        "condition_browse": {
            "mesh_term": [
                "Hyperparathyroidism", 
                "Hyperparathyroidism, Secondary", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multicenter, single-arm, extension study in which subjects with secondary\n      hyperparathyroidism currently receiving hemodialysis previously treated in AMG 20120231,\n      20120334, or 20120359 will continue to be treated with velcalcetide.  The study will assess\n      the long-term safety and tolerability of velcalcetide as well as measuring the intact\n      parathyroid hormone (iPTH), total serum albumin corrected calcium (cCa), and serum\n      phosphorous (P) values in these subjects during the course of their treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has provided informed consent prior to initiation of any study-specific\n             activities/procedures\n\n          -  Subject has completed treatment in Study 20120231 (also known as KAI-4169-008) or\n             Study 20120360, or has participated in Study 20120334 (also known as KAI-4169-005-01)\n\n          -  Female subjects who are: post menopausal (post menopausal is defined as no menses for\n             the previous 1 year and over the age of 50 years), surgically sterilized, have a\n             medical condition that prevents pregnancy, remain abstinent, or are willing to use\n             highly effective contraception during the study and for 3 months after the last dose.\n              Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test\n             within 2 weeks prior to the first dose of velcalcetide in the current study\n\n          -  Subject must be receiving hemodialysis 3 or 4 times weekly for at least 3 months\n\n        Exclusion Criteria:\n\n          -  Currently receiving treatment in another investigational device or drug study (other\n             than in one of the designated parent studies)\n\n          -  Subject has known sensitivity to any of the products or components to be administered\n             during dosing\n\n          -  Subject has been prescribed cinacalcet by the primary nephrologist between the\n             conclusion of the parent study and the start of dosing with velcalcetide in the\n             current study\n\n          -  Subject is receiving dialysis prescription dialysate calcium concentration < 2.25\n             mEq/L\n\n          -  Subject is pregnant or nursing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "815", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02102204", 
            "org_study_id": "20130213", 
            "secondary_id": [
                "2013-004136-30", 
                "KAI-4169"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Velcalcetide", 
            "description": "Subjects will be administered IV velcalcetide at the end of their regular dialysis sessions on a thrice weekly (TIW) schedule. Dose titration of velcalcetide is at the discretion of the Investigator and will be based upon the values of the local laboratory iPTH and cCa, with the frequency of these draws at the discretion of the Investigator. Subjects entering from the open-label parent studies AMG 416 20120231 or 20120334 will receive a starting dose of velcalcetide identical to the last dose received in the parent study. Subjects entering from the randomized, double-blind parent Study 20120360, will receive a starting dose of 5 mg velcalcetide. All subjects will continue to receive velcalcetide until approximately 2.5 years after the first subject enrolls.", 
            "intervention_name": "Velcalcetide", 
            "intervention_type": "Drug", 
            "other_name": "AMG 416 or KAI-4169"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Secondary Hyperparathyroidism (SHPT), chrominc kidney disease (CKD), hemodialysis", 
        "lastchanged_date": "March 31, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Minden", 
                    "country": "Germany", 
                    "zip": "32429"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 (Velcalcetide) in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Measure the subject incidence of adverse events reported", 
            "safety_issue": "Yes", 
            "time_frame": "2.5 Years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02102204"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Within 2x to 9x the upper limit of normal for the assay used", 
                "measure": "Measure the occurrence of iPTH value", 
                "safety_issue": "No", 
                "time_frame": "months 6, 12, and 18"
            }, 
            {
                "measure": "Measure the occurrence of P \u2264 4.6 mg/dL", 
                "safety_issue": "No", 
                "time_frame": "months 6, 12, and 18"
            }, 
            {
                "measure": "Assess the nature, frequency, severity, and relationship to treatment of all adverse events reported", 
                "safety_issue": "Yes", 
                "time_frame": "2.5 Years"
            }, 
            {
                "measure": "Occurrence of cCa concentration < 7.5 mg/dL", 
                "safety_issue": "Yes", 
                "time_frame": "months 6, 12, and 18"
            }, 
            {
                "measure": "Assess vital signs, antibody formation to velcalcetide, and changes in the laboratory parameters of albumin, total bilirubin (TBL), AST or ALT, and alkaline phosphatase", 
                "safety_issue": "Yes", 
                "time_frame": "2.5 Years"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}